Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A clinical association has been reported between type 1 Gaucher's disease, which is caused by a glucocerebrosidase deficiency owing to mutations in the glucocerebrosidase gene (GBA), and parkinsonism. We examined whether mutations in the GBA gene are relevant to idiopathic Parkinson's disease. METHODS: A clinic-based case series of 99 Ashkenazi patients with idiopathic Parkinson's disease, 74 Ashkenazi patients with Alzheimer's disease, and 1543 healthy Ashkenazi Jews who underwent testing to identify heterozygosity for certain recessive diseases were screened for the six GBA mutations (N370S, L444P, 84GG, IVS+1, V394L, and R496H) that are most common among Ashkenazi Jews. RESULTS: Thirty-one patients with Parkinson's disease (31.3 percent; 95 percent confidence interval, 22.2 to 40.4 percent) had one or two mutant GBA alleles: 23 were heterozygous for N370S, 4 were heterozygous for 84GG, 3 were homozygous for N370S, and 1 was heterozygous for R496H. Among the 74 patients with Alzheimer's disease, 3 were identified as carriers of Gaucher's disease (4.1 percent; 95 percent confidence interval, 0.0 to 8.5 percent): 2 were heterozygous for N370S, and 1 was heterozygous for 84GG. Ninety-five carriers of Gaucher's disease were identified among the 1543 control subjects (6.2 percent; 95 percent confidence interval, 5.0 to 7.4 percent): 92 were heterozygous for N370S, and 3 were heterozygous for 84GG. Patients with Parkinson's disease had significantly greater odds of being carriers of Gaucher's disease than did patients with Alzheimer's disease (odds ratio, 10.8; 95 percent confidence interval, 3.0 to 46.6; P<0.001) or control subjects (odds ratio, 7.0; 95 percent confidence interval, 4.2 to 11.4; P<0.001). Among the patients with Parkinson's disease, patients who were carriers of Gaucher's disease were younger than those who were not carriers (mean [+/-SD] age at onset, 60.0+/-14.2 years vs. 64.2+/-11.7 years; P=0.04). CONCLUSIONS: Our results suggest that heterozygosity for a GBA mutation may predispose Ashkenazi Jews to Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is a center for cellular signaling and signal integration, has responsibilities in trafficking cargo, and functionally interacts with other organelles.1,9”
From The lysosome and proteostatic stress at the intersection of pediatric neurological disorders and adult neurodegenerative diseases (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
From Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples (2010) · cites this paper as Aharon-Peretz et al. 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Research works printed but not linked: 1
- 10.1002/(sici)1098-1004(1998)12:4<240::aid-humu4>3.0.co;2-j · doi:10.1002/(sici)1098-1004(1998)12:4<240::aid-humu4>3.0.co;2-j
Cited by
Items 201–300 of 608
Luna, E., & Luk, K. C. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.10.023 · Cited by 67
Association between Parkinson's disease and glucocerebrosidase mutations in Brazil
Spitz, M., Rozenberg, R., Pereira, L. V., & Barbosa, E. R. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.06.010 · Cited by 65
“[14] 99 Israeli Jewish PD patients United Kingdom Brain Bank Criteria 6 mutat N370S, 84insG, IVS2+ V394L R496H Clark et al.”
BackgroundResultGlucocerebrosidase mutations and Parkinson disease
Vieira, S. R. L., & Schapira, A. H. V. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02531-3 · Cited by 71
“Over the last two decades, an association between GD and PD has been noticed, initially through case reports of parkinsonian symptoms among GD patients (Tayebi et al. 2003; Aharon-Peretz et al. 2004; Beavan et al. 2015) and confirmed by a large multicentre study (Sidransky et al.”
ResultNiemann-Pick C Disease Gene Mutations and Age-Related Neurodegenerative Disorders
Zech, M., Nübling, G., Castrop, F., Jochim, A., Schulte, E. C., Mollenhauer, B., Lichtner, P., Peters, A., Gieger, C., Marquardt, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082879 · Cited by 60
“Mutations in the GBA gene, which encodes the lysosomal enzyme deficient in Gaucher disease, are one of the commonest risk factors for PD, which was primarily shown in Ashkenazi Jewish individuals and subsequently in a number of other populations worldwide [37–41].”
BackgroundHarbo, H. F., Finsterer, J., Baets, J., Broeckhoven, C. V., Donato, S. D., Fontaine, B., Jonghe, P. D., Lossos, A., Lynch, T., Mariotti, C., et al. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02646.x · Cited by 69
Mai, A., Levy, D. H., Brown, A. K., Marriott, G., & Lü, B. (2019) · Scientific Reports · doi:10.1038/s41598-019-53844-5 · Cited by 66
Loss of HSPA9 induces peroxisomal degradation by increasing pexophagy
Jo, D. S., Park, S. J., Kim, A., Park, N. Y., Kim, J. B., Bae, J.-E., Park, H. J., Shin, J. H., Chang, J. W., Kim, P. K., et al. (2020) · Autophagy · doi:10.1080/15548627.2020.1712812 · Cited by 69
“Mutations of ATP13A2, lysosomal ATPase, and GBA, lysosomal glucocerebrosidase, genes have been identified in PD patients [58,59].”
BackgroundPreclinical diagnosis of parkinson’s disease: Are we there yet?
Siderowf, A. D., & Stern, M. B. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-006-0021-z · Cited by 76
Xing, Y., Tang, Y., Zhao, L., Wang, Q., Qin, W., Ji, X., Zhang, J., & Jia, J. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.09.028 · Cited by 63
“The PCR primers, annealing temperatures and restriction enzymes were according to the previous study [22].”
MethodA call for the creation of personalized medicine databases
Gurwitz, D., Lunshof, J. E., & Altman, R. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1931 · Cited by 63
“Individual response to pharmacotherapy is determined by pharmacokinetic and pharmacodynamic factors that often depend on the individual's genotyp”
BackgroundDodson, M. W., Leung, L. K., Lone, M., Lizzio, M. A., & Guo, M. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.017020 · Cited by 59
“Together with a striking amount of recent genetic data linking PD risk to genes involved in endolysosomal functions, including β-glucocerebrosidase (Aharon-Peretz et al., 2004; Gan-Or et al., 2008), ATP13A2 (Ramirez et al.”
BackgroundCeramides in Parkinson’s Disease: From Recent Evidence to New Hypotheses
Plotegher, N., Bubacco, L., Greggio, E., & Civiero, L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00330 · Cited by 68
Lysoplex: An efficient toolkit to detect DNA sequence variations in the autophagy-lysosomal pathway
Di Fruscio, G., Schulz, A., De Cegli, R., Savarese, M., Mutarelli, M., Parenti, G., Banfi, S., Braulke, T., Nigro, V., & Ballabio, A. (2015) · Autophagy · doi:10.1080/15548627.2015.1043077 · Cited by 62
Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease
Ruskey, J. A., Greenbaum, L., Roncière, L., Alam, A., Spiegelman, D., Liong, C., Levy, O. A., Waters, C., Fahn, S., Marder, K. S., et al. (2018) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2018.05.005 · Cited by 66
“[1] The association between GBA variants and PD was initially described in a study on brains of PD patients,[2] and later in the Ashkenazi-Jewish (AJ) population,[3, 4] but they are important in numerous other populations.”
BackgroundLysosomal trafficking defects link Parkinson's disease with Gaucher's disease
Wong, Y. C., & Krainc, D. (2016) · Movement Disorders · doi:10.1002/mds.26802 · Cited by 59
“Subsequent genetic studies in large cohorts found that PD patients with GBA1 mutations presented earlier with the disease and were more likely to have relatives affected with parkinsonism.(35,36) GBA1 mutations are now considered one of the most common risk factors for PD, with recent genome-wide associate studies of…”
BackgroundMutation analysis of Parkinson's disease genes in a Russian data set
Emelyanov, A., Usenko, T. S., Tesson, C., Senkevich, K. A., Nikolaev, M. A., Miliukhina, I. V., Kopytova, A. E., Timofeeva, A., Yakimovsky, A. F., Lesage, S., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.027 · Cited by 61
Gaucher disease – more than just a rare lipid storage disease
Roh, J., Subramanian, S., Weinreb, N. J., & Kartha, R. V. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02174-z · Cited by 60
“Subsequent studies reveal that GBA1 allele variants constitute the most prevalent known genetic risk factor for PD [145, 146].”
BackgroundHeterozygosity for a Mendelian disorder as a risk factor for complex disease
Sidransky, E. (2006) · Clinical Genetics · doi:10.1111/j.1399-0004.2006.00688.x · Cited by 71
“84insG, including three N370S homozygotes (66).”
The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews
Dagan, E., Schlesinger, I., Ayoub, M., Mory, A., Nassar, M., Kurolap, A., Peretz-Aharon, J., & Gershoni‐Baruch, R. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.06.016 · Cited by 64
“78 mean age at diagnosis); 99 of whom previously participated in our study linking GBA Ashkenazi founder mutations to PD [12] and 188 PD patients recruited thereafter, until 2013.”
BackgroundSelf-citationKim, Y.-M., Yum, M., Heo, S. H., Kim, T., Jin, H. K., Bae, J., Seo, G. H., Oh, A., Yoon, H. M., Lim, H. T., et al. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106132 · Cited by 60
Association between GBA L444P mutation and sporadic Parkinson's disease from Mainland China
Mao, X.-Y., Burgunder, J., Zhang, Z.-J., An, X., Zhang, J.-H., Yang, Y., Li, T., Wang, Y.-C., Chang, X. L., & Peng, R. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.12.007 · Cited by 62
Alquezar, C., Schoch, K. M., Geier, E. G., Ramos, E. M., Scrivo, A., Li, K. H., Argouarch, A. R., Mlynarski, E. E., Dombroski, B., DeTure, M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg3897 · Cited by 56
“The first gene to be recognized as such was glucocerebrosidase A (GBA), in which mutations can underlie both Gaucher’s and Parkinson’s disease (6), but many others have since been identified (7–9).”
BackgroundBoddupalli, C. S., Nair, S., Belinsky, G. S., Gans, J., Teeple, E. A., Nguyen, T., Mehta, S. S., Guo, L., Kramer, M. L., Ruan, J., et al. (2022) · eLife · doi:10.7554/elife.79830 · Cited by 57
“Moreover, heterozygous carriers of GBA1 mutations are at an increased risk of PD/LBD (Aharon-Peretz et al., 2004; Sidransky and Lopez, 2012; Sidransky et al., 2009).”
BackgroundGenome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes
Vacic, V., Ozelius, L. J., Clark, L. N., Bar‐Shira, A., Gana‐Weisz, M., Gurevich, T., Gusev, A., Kedmi, M., Kenny, E. E., Liu, X., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu158 · Cited by 63
“Mutations in the GBA gene occur in 13.7– 17.9% of Ashkenazi cases and 4.2–6.3% controls, compared with 5 and , 1% of non-Jewish European cases and controls (12,16–18).”
BackgroundInfluentialStrong association between glucocerebrosidase mutations and Parkinson's disease in Sweden
Ran, C., Brodin, L., Forsgren, L., Westerlund, M., Ramezani, M., Gellhaar, S., Xiang, F., Fardell, C., Nissbrandt, H., Söderkvist, P., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.022 · Cited by 60
“In particular, GBA mutations are more common in subjects with Ashkenazi Jewish ancestry (Aharon-Peretz et al., 2004; Gan-Or et al., 2008; Sidransky et al., 2009).”
BackgroundLipids in the Physiopathology of Hereditary Spastic Paraplegias
Darios, F. D., Mochel, F., & Stévanin, G. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00074 · Cited by 57
“Mutations in GBA1 have not been found in HSP patients, but loss of its paralog GBA2 is responsible for spastic ataxia with cognitive impairment (SPG46) (Hammer et al., 2013; Martin et al., 2013).”
BackgroundNew Genetic Insights into Parkinson's Disease
Feany, M. Β. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048263 · Cited by 56
The enigma of the E326K mutation in acid β-glucocerebrosidase
Horowitz, M., Pasmanik‐Chor, M., Ron, I., & Kolodny, E. H. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.07.002 · Cited by 59
Choi, J. M., Kim, W. C., Lyoo, C. H., Kang, S. Y., Lee, P. H., Baik, J. S., Koh, S., Ma, H., Sohn, Y. H., Lee, M. S., et al. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.02.035 · Cited by 61
Recent Developments in LRRK2-Targeted Therapy for Parkinson’s Disease
Zhao, Y., & Dzamko, N. L. (2019) · Drugs · doi:10.1007/s40265-019-01139-4 · Cited by 58
Gaucher Disease and the Synucleinopathies
Hruska, K. S., Göker-Alpan, Ö., & Sidransky, E. (2006) · BioMed Research International · doi:10.1155/jbb/2006/78549 · Cited by 56
“AharonPeretz et al [13], in a clinic-based series of 99 Ashkenazi patients from Northern Israel with classic PD, screened blood samples for six common mutations in glucocerebrosidase.”
Frequency of GBA Variants in Autopsy‐proven Multiple System Atrophy
Sklerov, M., Kang, U. J., Liong, C., Clark, L. N., Marder, K. S., Pauciulo, M. W., Nichols, W. C., Chung, W. K., Honig, L. S., Cortes, E. P., et al. (2017) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12481 · Cited by 55
Genetics of Parkinson’s disease and parkinsonism
Douglas, M. R., Lewthwaite, A. J., & Nicholl, D. J. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.6.657 · Cited by 52
Parkinson's disease: 10 years of progress, 1997–2007
Fahn, S. (2010) · Movement Disorders · doi:10.1002/mds.22796 · Cited by 55
Sun, Q., Guo, J., Wang, L., Yu, R., Zuo, X., Yao, L., Pan, Q., Xia, K., & Tang, B. (2010) · Movement Disorders · doi:10.1002/mds.23009 · Cited by 56
“whereas some studies found that age at disease onset did not differ in patients with GBA mutations compared with patients without mutations.(6,11,13,18,28) In our study, the 11 heterozygotes carrying the L444P mutation presented with a clinical picture indistinguishable from classical PD and had a good or excellent re…”
ResultBonifati, V. (2007) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(08)70008-7 · Cited by 60
“001) [39].”
GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted Therapy
Huh, Y. E., Usnich, T., Scherzer, C. R., Klein, C., & Chung, S. J. (2023) · Journal of Movement Disorders · doi:10.14802/jmd.23023 · Cited by 58
Zheng, J., Chen, L., Skinner, O. S., Ysselstein, D., Remis, J. P., Lansbury, P. T., Skerlj, R. T., Mrosek, M., Heunisch, U., Krapp, S., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b13003 · Cited by 52
Milestones of Parkinson’s Disease Research: 200 Years of History and Beyond
Li, S., & Le, W. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0178-2 · Cited by 54
“In 2003, mutations in NR4A2 were found to be associated with familial PD [29]; in 2004, the GBA mutation was identified as a risk factor for PD [30]; in 2010, Parkin–PINK1 interactions were reported to regulate mitophagy [31]; and in 2014, Nalls et al.”
BackgroundWang, R., Sun, H., Cao, Y., Zhang, Z., Chen, Y., Wang, X., Liu, L., Wu, J., Xu, H., Wu, D., et al. (2024) · Science Signaling · doi:10.1126/scisignal.adk8249 · Cited by 52
“Notably, in individuals with one single GBA mutation or in some patients with type I GD, there is an increased risk of developing Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) ( 4 – 6 ).”
BackgroundAging, cellular senescence and Parkinson's disease
Ma, Y., Erb, M. L., & Moore, D. J. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251316552 · Cited by 59
Genetic susceptibility in Parkinson's disease
Bras, J. M., & Singleton, A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.11.008 · Cited by 45
Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders
Lü, B., Ku, J., Flojo, R. A. B., Olson, C., Bengford, D., & Marriott, G. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114465 · Cited by 48
Parkinsons Disease: Genetics and Beyond
Inamdar, N., Arulmozhi, D. K., Tandon, A., & Bodhankar, S. L. (2007) · Current Neuropharmacology · doi:10.2174/157015907780866893 · Cited by 55
“Mutations are found in gene for glucocerebrosidase and the findings have been replicated by most studies [4, 160].”
ResultA Meta-Analysis of GBA-Related Clinical Symptoms in Parkinson’s Disease
Zhang, Y., Shu, L., Zhou, X., Pan, H., Xu, Q., Guo, J., Tang, B., & Sun, Q. (2018) · Parkinson's Disease · doi:10.1155/2018/3136415 · Cited by 41
Lin, C., Wei, P., Chen, C., Huang, Y., Lin, J.-L., Lo, Y., Lin, J.-L., Lin, C., Wu, Y., Chang, K., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00226 · Cited by 49
“, 2014), affecting autophagy activities (Aharon-Peretz et al., 2004; Gan-Or et al., 2015).”
Microglia orchestrate neuroinflammation
Feldman, R. A. (2022) · eLife · doi:10.7554/elife.81890 · Cited by 50
The effect of mutant GBA1 on accumulation and aggregation of α-synuclein
Maor, G., Rapaport, D., & Horowitz, M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz005 · Cited by 46
Targeting α‐synuclein: Therapeutic options
Dehay, B., Decressac, M., Bourdenx, M., Guadagnino, I., Fernagut, P., Tamburrino, A., Bassil, F., Meissner, W. G., & Bézard, E. (2016) · Movement Disorders · doi:10.1002/mds.26568 · Cited by 48
GBA1-Associated Parkinson’s Disease Is a Distinct Entity
Skrahin, A., Horowitz, M., Istaiti, M., Skrahina, V., Lukáš, J., Yahalom, G., Cohen, M. E., Revel‐Vilk, S., Göker-Alpan, Ö., Becker‐Cohen, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137102 · Cited by 48
Difference in MSA Phenotype Distribution between Populations: Genetics or Environment?
Ozawa, T., Révész, T., Paviour, D. C., Lees, A. J., Quinn, N. P., Tada, M., Kakita, A., Onodera, O., Wakabayashi, K., Takahashi, H., et al. (2012) · Journal of Parkinson s Disease · doi:10.3233/jpd-2012-11056 · Cited by 44
“Mutations in the glucocerebrosidase gene coding for lysosomal beta-glucocerebrosidase have recently been found to be a risk factor for PD and dementia with Lewy bodies [70–76]; however, these mutations have not been found in patients with MSA [77, 78].”
Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
Dinur, T., Bauer, P., Beetz, C., Kramp, G. J., Cozma, C., Iurascu, M. I., Becker‐Cohen, M., Istaiti, M., Rolfs, A., Zimran, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031627 · Cited by 46
“Although considerable clinical variation is seen [33], GBA-associated PD is typically associated with an earlier age of onset, a faster deterioration of motor functions, and a higher frequency and faster progression of cognitive decline compared to non GBA-associated PD, thus highlighting the importance of detection o…”
BackgroundInduced pluripotent stem cells for modeling neurological disorders
Russo, F. B., Cugola, F. R., Fernandes, I. R., Pignatari, G. C., & Beltrão-Braga, P. C. B. (2015) · World Journal of Transplantation · doi:10.5500/wjt.v5.i4.209 · Cited by 48
Ose, N. J., Butler, B. M., Kumar, A., Kazan, I. C., Sanderford, M. D., Kumar, S., & Ozkan, S. B. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010006 · Cited by 46
“We illustrate the approach using structural dynamics by considering the example of a single mutant N370S that is present with a high frequency (~70%) in the Ashkenazi Jewish population and studied extensively [27,32].”
MethodPLA2G6 variant in Parkinson's disease
Tomiyama, H., Yoshino, H., Ogaki, K., Li, L., Yamashita, C., Li, Y., Funayama, M., Sasaki, R., Kokubo, Y., Kuzuhara, S., et al. (2011) · Journal of Human Genetics · doi:10.1038/jhg.2011.22 · Cited by 43
Wu, G., Yan, B., Wang, X., Feng, X., Zhang, A., Xu, X., & Dong, H. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.04.011 · Cited by 45
Cognitive impairment and dementia in Parkinson's disease
Marder, K. S. (2010) · Movement Disorders · doi:10.1002/mds.22787 · Cited by 48
Glucosidase-beta variations and Lewy body disorders
Farrer, M. J., Williams, L. N., Algom, A. A., Kachergus, J., Hulihan, M. M., Ross, O. A., Rajput, A., Papapetropoulos, S., Mash, D. C., & Dickson, D. W. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.08.004 · Cited by 42
“However, the positive association is driven by three studies in which subjects were exclusively or predominantly from the Ashkenazi Jewish population [4,5,7].”
BackgroundMolecular genetic pathways in Parkinson's disease: a review
Jain, S., Wood, N. W., & Healy, D. G. (2005) · Clinical Science · doi:10.1042/cs20050106 · Cited by 52
The significance of GBA for Parkinson's disease
Brockmann, K., & Berg, D. (2014) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-014-9714-7 · Cited by 45
“(Aharon-Peretz et al 2004).”
BackgroundInfluentialThe ceramide transporter and the Goodpasture antigen binding protein: one protein – one function?
Mencarelli, C., Losen, M. H., Hammels, C., Vry, J. D., Hesselink, M. K. C., Steinbusch, H. W. M., Baets, M. H. D., & Martínez‐Martínez, P. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06673.x · Cited by 45
“Moreover, Sidransky and colleagues found that heterozygous mutations that occur in the enzyme glucosylcerebrosidase pre-dispose to PD (Aharon-Peretz et al. 2004; Bras et al. 2009) and Lewy body disorders (Mata et al.”
BackgroundPluvinage, J. V., Sun, J., Claes, C., Flynn, R. A., Haney, M. S., Iram, T., Meng, X., Lindemann, R. C., Riley, N. M., Danhash, E., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg2919 · Cited by 41
“For example, autosomal recessive mutations in the glucocerebrosidase gene, which encodes a lysosomal enzyme necessary for glycosphingolipid degradation, cause Gaucher’s disease, whereas heterozygous carriers are predisposed to Parkinson’s disease (4).”
BackgroundClassification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review
Rossi, M., Schaake, S., Usnich, T., Boehm, J., Steffen, N., Schell, N., Krüger, C., Gül, T., Bahr, N., Kleinz, T., et al. (2025) · Movement Disorders · doi:10.1002/mds.30141 · Cited by 42
Impact of ethnicity on the natural history of Parkinson disease
Sauerbier, A., Aris, A., Lim, E. W., Bhattacharya, K., & Chaudhuri, К. R. (2018) · The Medical Journal of Australia · doi:10.5694/mja17.01074 · Cited by 40
α‐Synuclein abnormalities in mouse models of peroxisome biogenesis disorders
Yakunin, E., Moser, A., Loeb, V., Saada, A., Faust, P., Crane, D. I., Baes, M., & Sharon, R. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22246 · Cited by 39
“Importantly, homozygous mutations in the glucocerebrosidase gene causing the glycosphingolipid storage disorder Gaucher’s disease were recently shown to be linked to familial forms of PD in diverse populations (Aharon-Peretz et al., 2004).”
BackgroundDrosophila melanogaster Mutated in its GBA1b Ortholog Recapitulates Neuronopathic Gaucher Disease
Cabasso, O., Paul, S., Dorot, O., Maor, G., Krivoruk, O., Pasmanik‐Chor, M., Mirzaian, M., Ferraz, M. J., Aerts, J. M. F. G., & Horowitz, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091420 · Cited by 38
“Type 1 GD patients have significantly higher propensity to develop Parkinson’s disease (PD) in comparison to the non-GD population [9] (for a review, see [10]).”
BackgroundHuang, C., Chou, Y. W., Lai, S. ‐., Chang, H. ‐., Yeh, T. ‐., Weng, Y.-H., Chen, R. ‐., Huang, Y., & Lu, C. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03362.x · Cited by 41
Gene panels and primers for next generation sequencing studies on neurodegenerative disorders
Giau, V. V., An, S. S. A., Bagyinszky, E., & Kim, S. (2015) · Molecular & Cellular Toxicology · doi:10.1007/s13273-015-0011-9 · Cited by 40
Sauerbier, A., Jitkritsadakul, O., Titova, N., Klingelhoefer, L., Tsuboi, Y., Carr, H. J., Kumar, H., Banerjee, R., Erro, R., Bhidayasiri, R., et al. (2017) · Neuroepidemiology · doi:10.1159/000478702 · Cited by 44
Kumar, D. T., Eldous, H. G., Mahgoub, Z. A., Doss, C. G. P., & Zayed, H. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0286-3 · Cited by 37
Mandel, S. A., Morelli, M., Halperin, I. J. Y., & Korczyn, A. D. (2010) · The EPMA Journal · doi:10.1007/s13167-010-0036-z · Cited by 39
“These mutations are most common among the Ashkenazi-Jewish population [131, 132].”
BackgroundThe Association Between ß-Glucocerebrosidase Mutations and Parkinsonism
Swan, M. C., & Saunders-Pullman, R. J. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0368-x · Cited by 39
Glucocerebrosidase mutations in Thai patients with Parkinson's disease
Pulkes, T., Choubtum, L., Chitphuk, S., Thakkinstian, A., Pongpakdee, S., Kulkantrakorn, K., Hanchaiphiboolkul, S., Tiamkao, S., & Boonkongchuen, P. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.06.007 · Cited by 37
“The association between the heterozygous GBA mutations and PD was then further supported by a study on the Ashkenazi cohort showing that PD patients had significantly higher odds for carrying the common GBA mutations than patients having Alzheimer's disease and healthy subjects [5].”
BackgroundResultKnowledge of and Interest in Genetic Results Among Parkinson Disease Patients and Caregivers
Sakanaka, K., Waters, C., Levy, O. A., Louis, E. D., Chung, W. K., Marder, K. S., & Alcalay, R. N. (2013) · Journal of Genetic Counseling · doi:10.1007/s10897-013-9618-y · Cited by 35
Clinical heterogeneity of ATP13A2 linked disease (Kufor-Rakeb) justifies a PARK designation
Lees, A. J., & Singleton, A. B. (2007) · Neurology · doi:10.1212/01.wnl.0000265228.66664.f4 · Cited by 35
Glucocerebrosidase gene mutations are associated with Parkinson's disease in Russia
Emelyanov, A., Boukina, T., Yakimovskii, А. F., Usenko, T., Drosdova, A., Zakharchuk, A., Andoskin, P. A., Dubina, M., Schwarzman, A. L., & Пчелина, С. Н. (2011) · Movement Disorders · doi:10.1002/mds.23950 · Cited by 34
Glucocerebrosidase L444P mutation confers genetic risk for Parkinson’s disease in central China
Wang, Y., Liu, L., Xiong, J., Zhang, X., Chen, Z., Yu, L., Chen, C., Huang, J., Zhang, Z., Mohmed, A. A., et al. (2012) · Behavioral and Brain Functions · doi:10.1186/1744-9081-8-57 · Cited by 35
“R120W primers were obtained from previous studies [15,17].”
MethodResultSharma, S., & Priya, S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2340-9 · Cited by 34
Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease
Vieira, S. R. L., Mezabrovschi, R., Toffoli, M., Pozo, S. L. D., Menozzi, E., Mullin, S., Yalkic, S., Limbachiya, N., Koletsi, S., Loefflad, N., et al. (2024) · Movement Disorders · doi:10.1002/mds.30006 · Cited by 33
“34,65,66 GBA1 variants harbor a dose and variant-type effect, with an earlier PD onset also reported in patients with biallelic (homozygous or compound heterozygous) GBA1 variants relative to heterozygotes, 67 and in carriers of severe variants (5 years earlier) compared with mild variants.”
Ren, J., Zhang, R., Pan, C., Xu, J., Sun, H., Hua, P., Zhang, L., Zhang, W., Xu, P., Ma, C., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15230 · Cited by 33
Hu, F., Xi, J., Guo, J., Yu, L., Liu, L., He, X., Liu, Z.-L., Zou, X. ‐., & Xu, Y. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03097.x · Cited by 36
“The recent report of an association between the glucocerebrosidase (GBA) gene N370S mutation and Parkinson s disease (PD) in Ashkenazi Jews stimulated heightened interest amongst researchers in the field [1].”
BackgroundKono, S., Shirakawa, K., Ouchi, Y., Sakamoto, M., Ida, H., Sugiura, T., Tomiyama, H., Suzuki, H., Takahashi, Y., Miyajima, H., et al. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.10.019 · Cited by 32
Zhao, F., Bi, L., Wang, W., Wu, X., Li, Y., Gong, F., Lu, S., Feng, F., Qian, Z., Hu, C., et al. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.02.007 · Cited by 33
“…that the underlying causes of CBA mutations leading to Parkinson’s disease were likely to be related to the faulty processing of toxic, unwanted proteins, exacerbation of the relative decrease in glucocerebrosidase activity and accumulation of glucocerebroside (Aharon-Peretz et al., 2004).”
Jiang, Z., Huang, Y., Zhang, P., Han, C., Lu, Y., Mo, Z., Zhang, Z., Li, X., Zhao, S., Cai, F., et al. (2020) · Molecular Brain · doi:10.1186/s13041-020-00637-x · Cited by 32
“001) by screening six common GBA mutations [10].”
BackgroundFonseca‐Ornelas, L., Stricker, J. M. S., Soriano-Cruz, S., Weykopf, B., Dettmer, U., Muratore, C., Scherzer, C. R., & Selkoe, D. J. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00380-1 · Cited by 32
Parkinsonism in Gaucher's disease type 1: Ten new cases and a review of the literature
Kraoua, I., Stirnemann, J., Ribeiro, M. J., Rouaud, T., Vérin, M., Annic, A., Rosé, C., Defebvre, L., Réménieras, L., Schüpbach, M. W. M., et al. (2009) · Movement Disorders · doi:10.1002/mds.22593 · Cited by 31
Genetic Movement Disorders in Patients of Jewish Ancestry
Inzelberg, R., Hassin‐Baer, S., & Jankovic, J. J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1364 · Cited by 31
Carubbi, F., Cappellini, M. D., Fargion, S. R., Fracanzani, A. L., & Nascimbeni, F. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.01.004 · Cited by 31
“However, this classification is somewhat artificial, since GD actually manifests as a clinical continuum; indeed, it is now clear that also type 1 GD may be associated with neurologic manifestations, in particular movement disorders and Parkinson disease [4,6].”
BackgroundThe annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1
Gustavsson, E. K., Sethi, S., Gao, Y., Brenton, J. W., García-Ruiz, S., Zhang, D., Garza, R., Reynolds, R. H., Evans, J. R., Chen, Z., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk1296 · Cited by 30
New Directions in Gaucher Disease
Horowitz, M., Elstein, D., Zimran, A., & Göker-Alpan, Ö. (2016) · Human Mutation · doi:10.1002/humu.23056 · Cited by 36
“Other radioligands, such as [11C]CFT and [11C]raclopride demonstrated that GBA-related Parkinsonism is associated with presynaptic dopaminergic dysfunction [Kono et al., 2007].”
BackgroundInfluentialCLEC16A—An Emerging Master Regulator of Autoimmunity and Neurodegeneration
Pandey, R., Bakay, M. A., & Hakonarson, H. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098224 · Cited by 32
“Familial cases of PD are caused by mutations in the SNCA (PARK1) [89], Parkin (PARK2) [90], DJ-1 (PARK7) [91], PINK1 (PARK6) [92], LRRK2 (PARK8) [93,94], ATP13A2 (PARK9), VPS13C [95–97] and GBA [98], all well-established single gene disorders.”
Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease
Noelker, C., Lü, L., Höllerhage, M., Vulinović, F., Sturn, A., Roscher, R., Höglinger, G. U., Hirsch, É. C., Oertel, W. H., Alvarez‐Fischer, D., et al. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.06.030 · Cited by 31
“Moreover, this association appears not to be restricted to Ashkenazi Jews, as initially suggested [6], but is present”
BackgroundVrancken, A. F. J. E. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.073239 · Cited by 30
Interaction Map and Selection of microRNA Targets in Parkinson′s Disease‐Related Genes
Shinde Santosh, P., Arora, N., Sarma, P. N., Pal‐Bhadra, M., & Bhadra, U. (2009) · BioMed Research International · doi:10.1155/2009/363145 · Cited by 33
Update on Genetics of Parkinsonism
Fujioka, S., & Wszołek, Z. K. (2012) · Neurodegenerative Diseases · doi:10.1159/000334285 · Cited by 29
LRRK2 and Lipid Pathways: Implications for Parkinson’s Disease
Galper, J., Kim, W. S., & Dzamko, N. L. (2022) · Biomolecules · doi:10.3390/biom12111597 · Cited by 30
The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson’s therapeutics
Rubilar, J. C., Outeiro, T. F., & Klein, A. D. (2024) · Brain · doi:10.1093/brain/awae070 · Cited by 31
Bendikov-Bar, I., Rapaport, D., Larisch, S., & Horowitz, M. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-9-86 · Cited by 29
“There is a significantly higher propensity of GD patients or carriers of GD mutations to develop Parkinson’s disease (PD) compared to the general population [5-19], indicating that not only GD pathology but even the presence of one mutant GBA allele increases the risk for the development of PD.”
BackgroundLysosomal Proteins as a Therapeutic Target in Neurodegeneration
Donald, J. M. M., & Krainc, D. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-050715-104432 · Cited by 31
Membrane Trafficking Illuminates a Path to Parkinson’s Disease
Hasegawa, T., Sugeno, N., Kikuchi, A., Baba, T., & Aoki, M. (2017) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.242.63 · Cited by 31
Metadata
- Authors
- Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- ORCID
- Rosenbaum, Hanna
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-04
- Volume
- 351
- Issue
- 19
- Pages
- 1972-1977
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992253341
- Cited by
- 597
- References
- 32
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 17 · 2023: 21 · 2022: 32 · 2021: 27 · 2020: 16 · 2019: 25 · 2018: 26 · 2017: 32 · 2016: 35 · 2015: 29 · 2014: 28 · 2013: 39 · 2012: 28
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase gene, GBA mutations, Ashkenazi Jews, N370S mutation, Alzheimer's disease, parkinsonism, genetic screening, heterozygosity, genotype-phenotype correlation, gene-environment interaction
- MeSH terms
- Alzheimer Disease, DNA Mutational Analysis, Female, Glucosylceramidase, Heterozygote, Humans, Jews, Male, Mutation, Parkinson Disease, Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.